# Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

> **NCT04577404** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 124 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** MT-1186

## Key facts

- **NCT ID:** NCT04577404
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2023-08-09
- **Final completion:** 2023-08-09
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04577404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04577404, "Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04577404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*